US Bancorp’s BioAtla BCAB Stock Holding History

US Bancorp’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	-$1K	–	4079
2022 Q1	$1K	Buy	5 +1	+25%	+$418	﹤0.01%	3912
2021 Q4	$3K	Sell	4 -3	-43%	-$3.84K	﹤0.01%	3772
2021 Q3	$11K	Buy	7 +6	+600%	+$11.7K	﹤0.01%	3389
2021 Q2	$2K	Buy	+1	New	+$2.26K	﹤0.01%	3799

Other funds holding BCAB

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

US Bancorp's BCAB Position: Q2 2022 in Review

US Bancorp sold out of BioAtla (BCAB) in Q2 2022, closing a stake of 5 shares — an estimated $1K sold.

US Bancorp first reported a position in BCAB in Q2 2021 and held it in 4 quarters. The position peaked at $11K in Q3 2021. 76 funds tracked by Wall St. Rank hold BCAB as of Q2 2022.

US Bancorp reported no remaining BioAtla position as of Q2 2022 after selling out during the quarter.
US Bancorp sold 5 BioAtla shares in Q2 2022, an estimated $1K.
US Bancorp first reported a position in BioAtla in Q2 2021 and held it in 4 quarters.
US Bancorp's BioAtla position peaked at $11K in Q3 2021.
76 funds tracked by Wall St. Rank held BioAtla as of Q2 2022.

Based on US Bancorp's 13F filing for Q2 2022, filed 1 Aug 2022.